Alignment Healthcare (ALHC) Insider Sells $550,000 in Stock

Alignment Healthcare, Inc. (NASDAQ: ALHC) operates Medicare Advantage plans through a technology-integrated platform targeting high-need senior populations. An executive share sale this week drew attention — but the underlying Q1 numbers and a year-to-date stock surge of more than 56% are the more consequential story.

At a Glance

• ALHC trading at $21.66, up 3.1% on the session as of June 21, 2026
• Market cap: $4.52 billion; 52-week range: $13.05–$22.74
• Trailing twelve-month revenue: $4.26 billion; net income: $19.81 million
• EVP Joseph Konowiecki sold 25,000 shares on June 18 under a prearranged Rule 10b5-1 plan

The Insider Sale in Context

According to an SEC Form 4 filed this week, Joseph S. Konowiecki, Alignment Healthcare's Executive Vice President of Corporate Affairs, sold 25,000 shares in an open-market transaction on June 18, 2026, at a reported price of $22.00 per share — a total transaction value of $550,000. After the sale, Konowiecki retained direct ownership of 1,153,816 shares, valued at roughly $25.2 million based on the June 18 market close of $21.86.

The disposal represented just over 2% of his direct holdings. Critically, the trade was executed under a Rule 10b5-1 trading plan adopted in March, meaning it was structured months before execution and insulated from real-time knowledge of material non-public information. That structure significantly limits what can be inferred about management's view of the stock at this moment.

Konowiecki's remaining stake of more than 1.15 million shares keeps him substantially aligned with shareholders. If the sale were a signal of concern, the math makes it a quiet one.

First-Quarter Results Tell a Stronger Story

The more meaningful data point for ALHC isn't the insider transaction — it's the Q1 operating performance that preceded it. Revenue jumped 33.3% year over year to $1.24 billion, while membership expanded 30.9% to approximately 284,800 members. Those are not the metrics of a company stumbling through a difficult Medicare Advantage cycle.

The company also swung from a net loss in the year-ago period to net income of $11.4 million. Adjusted EBITDA grew nearly 88% to $37.9 million. Following those results, management raised the midpoint of full-year guidance across four metrics: membership, revenue, adjusted gross profit, and adjusted EBITDA. CEO John Kao described the quarter as evidence of Alignment's capacity to "grow with discipline," citing progress in sales, clinical operations, and cost management.

For a company that only recently crossed into consistent profitability on a trailing basis — TTM net income of $19.81 million on $4.26 billion in revenue — that guidance lift carries real weight.

What the Numbers Say

Valuation

At $21.66, ALHC sits near the upper end of its 52-week range of $13.05 to $22.74 — the stock has essentially doubled off its lows in roughly a year. The 56.59% one-year price gain (measured to June 18) means the market is pricing in sustained execution. With thin net margins in the low single digits on a TTM basis, the stock is valued on growth trajectory rather than current earnings power. The source data does not supply a conventional P/E ratio, which is consistent with a company still building toward normalized profitability.

Momentum

An RSI of 66.94 puts ALHC close to — but not yet at — technically overbought territory. The reading reflects sustained buying pressure without the kind of parabolic spike that typically precedes a sharp correction. Today's 3.1% session gain pushed the stock toward $21.66 against a 52-week high of $22.74, leaving about 5% of headroom before the stock tests its annual ceiling.

Yield

Alignment Healthcare does not pay a dividend. Capital allocation is directed toward growth investment rather than income distribution, which is typical for a company at this stage of scaling a managed care platform. Income-oriented investors will find no yield support here.

Bull Case

The Medicare Advantage market is structurally growing as Baby Boomers age into eligibility, and scale matters enormously in managed care — Alignment's 30%-plus membership growth suggests it is capturing share. If adjusted EBITDA margins continue to expand and the company converts operating leverage into durable net income, the current valuation could look reasonable in retrospect. Raised guidance from management provides near-term earnings visibility.

Bear-Case Risks

Medicare Advantage reimbursement rates are set by the federal government and subject to annual revision — adverse rate changes could compress margins quickly, particularly for a company still building its profit cushion. At nearly $22, the stock is priced for continued execution; any operational stumble or membership miss would likely be punished sharply given the run the shares have already had. The RSI approaching 70 also suggests the easy money from the recent rally may already be in the price.

Frequently Asked Questions

Why did Alignment Healthcare's EVP sell shares?

Joseph Konowiecki sold 25,000 shares on June 18, 2026 under a Rule 10b5-1 trading plan adopted in March 2026. These plans are structured in advance and executed automatically, reducing the informational significance of the timing.

How large is Alignment Healthcare's Medicare Advantage business?

As of Q1 2026, Alignment served approximately 284,800 members, up 30.9% year over year. Trailing twelve-month revenue stood at $4.26 billion.

Does ALHC pay a dividend?

No. Alignment Healthcare does not currently pay a dividend. The company is reinvesting capital into membership and platform growth.

What is the significance of the Rule 10b5-1 plan?

A Rule 10b5-1 plan allows corporate insiders to establish a preset schedule for stock sales, providing an affirmative defense against insider trading allegations. Trades executed under such plans are generally not considered to reflect a view on near-term stock performance.

Where ALHC Stands Heading Into the Second Half

Alignment Healthcare enters the back half of 2026 with accelerating membership growth, expanding margins, raised guidance, and a stock price that has validated the bull thesis — at least so far. The insider sale is a non-event procedurally. The harder question is whether the company's operational momentum can justify a share price now within striking distance of its 52-week high. Management's Q1 results suggest the answer may be yes, but with an RSI near 67 and the stock above $21, there is less margin for error than there was a year ago at $13.